Deep Track Capital, LP Expands Nurix Therapeutics Inc (NRIX) Sta
Deep Track Capital, LP increased its stake in Nurix Therapeutics Inc (NRIX) by purchasing 1,391,211 shares, bringing its total holdings to 7,736,455 shares. Nurix Therapeutics, a clinical-stage biopharmaceutical company, is considered significantly overvalued by GuruFocus's GF Value, trading at 286% above its intrinsic value despite strong market momentum. Deep Track Capital's move aligns with its strategy of investing in high-potential biotech firms, while financial health indicators for Nurix show strong liquidity but ongoing unprofitability.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in the life sciences sector, with a strong background in scaling organizations through growth and preparing for commercialization. His appointment comes as Nurix transitions from a research-focused company to a fully integrated biopharmaceutical organization, aiming to advance its clinical pipeline and prepare for the commercial launch of its targeted protein degradation medicines.
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics (Nasdaq: NRIX) has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in life sciences and will join the company's Executive Management Team. His role will be crucial as Nurix transitions from a research and early clinical-stage company to a fully integrated biopharmaceutical organization, preparing for commercialization and scaling its operations.
Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right?
Nurix Therapeutics (NRIX) has seen increased investor attention following the start of a Phase 3 trial for bexobrutideg and a $10 million milestone payment from Sanofi. The stock has experienced significant positive momentum over the past year. While its Price-to-Book ratio of 7x appears rich compared to the broader biotech industry, it is cheaper than its direct peer group, suggesting a balanced market valuation despite ongoing losses.
Handelsbanken Fonder AB Buys 86,000 Shares of Nurix Therapeutics, Inc. $NRIX
Handelsbanken Fonder AB increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 15.7% in the second quarter, acquiring an additional 86,000 shares, bringing its total holdings to 633,000 shares valued at approximately $15.4 million. Despite this institutional buying, insiders sold a significant number of shares, and Nurix reported quarterly earnings and revenue below analyst expectations. Analyst sentiment remains "Moderate Buy" with a consensus price target of $34.21, although some analysts have adjusted their ratings and price targets.
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche
Nurix Therapeutics (NRIX) saw its stock rise 6.0% after achieving a US$10 million milestone payment from Sanofi for advancing its oral STAT6 degrader into a Phase 1 trial. Concurrently, the company, in partnership with Roche, began a global Phase 3 study for its BTK degrader bexobrutideg, enrolling the first patient for relapsed or refractory CLL/SLL. These developments highlight Nurix's DEL-AI platform's progress into late-stage clinical programs and its ability to generate partnership revenues.
Nurix Therapeutics stock hits 52-week high at $26.40 By Investing.com
Nurix Therapeutics (NRIX) stock has reached a 52-week high of $26.40, marking a 1-year return of 159%, and is currently trading near its Fair Value with a market capitalization of $2.72 billion. Analysts predict the company will achieve profitability this year with an expected EPS of $3.80. Recent analyst updates from Mizuho, Truist Securities, Baird, and Morgan Stanley reflect strong confidence, particularly due to a significant collaboration deal with Roche for the drug bexdeg, leading to raised price targets.
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche
Nurix Therapeutics received a US$10 million milestone payment from Sanofi for advancing an oral STAT6 degrader into a Phase 1 trial and initiated a global Phase 3 study with Roche for its BTK degrader bexobrutideg. These developments highlight the progression of Nurix's DEL-AI platform into late-stage clinical programs and demonstrate tangible partnership revenues. The company's investment narrative is centered on its platform translating into clinical success and non-dilutive funding, with the Roche collaboration providing a significant registrational-stage catalyst.
Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche
Nurix Therapeutics (NRIX) saw a 6.0% stock increase after announcing a US$10 million milestone payment from Sanofi for advancing an oral STAT6 degrader into a Phase 1 trial and enrolling the first patient in a global Phase 3 study for its BTK degrader bexobrutideg with Roche. These developments highlight the success of Nurix’s DEL-AI protein degradation platform in generating late-stage clinical programs and partnership revenues. While the Sanofi payment is small compared to Nurix's R&D spend, it de-risks the platform, with future BTK degrader data and milestones from Roche and Sanofi remaining key factors for investors.
Nurix Therapeutics stock hits 52-week high at $26.40
Nurix Therapeutics Inc. (NRIX) stock has reached a new 52-week high of $26.40, marking a 159% return over the past year. Analysts expect the company to be profitable this year, with EPS projected at $3.80, and major firms like Mizuho, Truist Securities, Baird, and Morgan Stanley have raised price targets following a collaboration deal with Roche.
Sei Investments Co. Buys 46,132 Shares of Nurix Therapeutics, Inc. $NRIX
Sei Investments Co. significantly increased its stake in Nurix Therapeutics (NASDAQ:NRIX) during the first quarter, purchasing an additional 46,132 shares and bringing its total holdings to 82,108 shares valued at $1.27 million. Despite recent weaker-than-expected quarterly earnings and insider share sales, analysts largely maintain a "Moderate Buy" consensus rating with an average price target of $34.21, significantly above the stock's current trading price. Several other institutional investors also established or expanded their positions in Nurix Therapeutics.
Renaissance Technologies LLC Invests $1.83 Million in Nurix Therapeutics, Inc. $NRIX
Renaissance Technologies LLC recently acquired a new position in Nurix Therapeutics, Inc. worth approximately $1.83 million during the first quarter. Despite this institutional investment and a "Moderate Buy" consensus rating from analysts, Nurix Therapeutics reported weaker-than-expected quarterly results, including an EPS loss of $0.81 against an estimated $0.73, and revenue significantly below expectations. Additionally, company insiders have sold over 25,000 shares in the last three months.
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High After Analyst Upgrade
Nurix Therapeutics (NASDAQ:NRIX) reached a new 52-week high after Royal Bank of Canada raised its price target from $33 to $36, maintaining an "outperform" rating. Despite positive analyst sentiment with a "Moderate Buy" consensus, the company continues to report financial losses, missing revenue and EPS expectations in its latest quarterly results. Insiders have also recently sold shares, though institutional investors have shown mixed activity, with some increasing their holdings.
Royal Bank Of Canada Boosts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00
Royal Bank of Canada increased its price target for Nurix Therapeutics (NASDAQ:NRIX) from $33.00 to $36.00, maintaining an "outperform" rating, indicating a potential 40.7% upside. This adjustment comes despite the company missing quarterly earnings and revenue estimates, and notable insider selling. Overall analyst sentiment remains positive, with a "Moderate Buy" consensus and an average price target of $34.21.
Why Nurix Therapeutics (NRIX) Is Back In The Spotlight
Nurix Therapeutics (NRIX) is gaining investor attention following the enrollment of the first patient in its Phase 3 DAYBreak CLL-306 trial for bexobrutideg and a $10 million milestone payment from Sanofi. The company has seen significant share price appreciation over the past year, although its price-to-book ratio of 6.6x suggests it's expensive compared to the broader US Biotechs industry average, yet appears reasonable against a closer peer group. Investors are weighing the potential rewards from clinical progress against risks such as ongoing losses and trial outcomes.
Dimensional Fund Advisors LP Purchases 349,710 Shares of Nurix Therapeutics, Inc. $NRIX
Dimensional Fund Advisors LP significantly increased its stake in Nurix Therapeutics, Inc. by 81.1%, purchasing an additional 349,710 shares to hold a total of 780,696 shares valued at $12.1 million. This comes despite Nurix Therapeutics reporting weaker-than-expected quarterly results, including a wider loss per share and lower revenue than anticipated. The stock maintains a consensus "Moderate Buy" rating from analysts with an average price target of $34.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of "Moderate Buy" by Brokerages
Nurix Therapeutics (NASDAQ:NRIX) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month price target of $34.00, significantly above its current trading price of $25.53. Several analysts, including those from Stifel, HC Wainwright, BTIG Research, Royal Bank Of Canada, and Jefferies Financial Group, recently raised their price targets and reiterated positive ratings. Despite this, the company reported weaker-than-expected quarterly results and saw insider selling of 25,314 shares worth approximately $589,000 over the past 90 days.
Nurix Therapeutics (NASDAQ:NRIX) Rating Increased to Hold at Wall Street Zen
Wall Street Zen has upgraded Nurix Therapeutics (NASDAQ:NRIX) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with an average price target of $34.00. The company's shares opened at $25.53, nearing their 52-week high, and have shown performance above their 50-day and 200-day moving averages. Despite the rating upgrade, Nurix Therapeutics recently missed earnings estimates, reporting a quarterly loss of $0.81 per share on $9.04 million in revenue, and insiders have sold over $589,361 worth of shares in the past 90 days.
Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 4,356 Shares of Stock
Nurix Therapeutics insider Gwenn Hansen sold 4,356 shares of NRIX stock for $108,900 at $25 per share, reducing her ownership by 3.58%. This transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving her with 117,227 shares. Despite a quarterly loss and missed revenue estimates, the company has made pipeline progress, including a $10 million milestone payment for a Phase 1 trial initiation and first-patient enrollment in a Phase 3 leukemia trial, leading analysts to maintain a "Moderate Buy" rating with an average price target of $34.
How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche
Nurix Therapeutics has reached two significant milestones: a $10 million payment from Sanofi for a STAT6 degrader trial and the enrollment of the first patient in a global Phase 3 study of bexobrutideg with Roche. These advancements underscore Nurix's DEL-AI discovery platform and partnering model, transforming early research into late-stage clinical trials. While the company faces risks such as high losses and reliance on partners, the progression of bexobrutideg into a registrational Phase 3 study with Roche solidifies its potential for a future commercial product and shared economics.
Nurix Therapeutics stock hits 52-week high at $25.22
Nurix Therapeutics Inc. (NRIX) stock hit a 52-week high, closing at $25.22, marking a 140.54% increase over the past year and a 55% gain in the last six months. This surge is likely driven by strong investor confidence and strategic developments, including a significant collaboration deal with Roche for bexdeg. Analysts from Mizuho, Truist Securities, Baird, and Morgan Stanley have all raised their price targets for Nurix, maintaining positive ratings.
Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins
Nurix Therapeutics (NRIX) has announced a $10 million milestone payment from Sanofi for the first-in-human trial of an oral STAT6 degrader and the enrollment of the first patient in a pivotal Phase 3 trial for bexobrutideg with Roche. These developments highlight Nurix's progress in targeted protein degradation and its expanded collaborations with major pharmaceutical companies. Despite the positive news, analysts note risks including expected earnings decline and shareholder dilution.
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High - Still a Buy?
Nurix Therapeutics (NASDAQ:NRIX) recently hit a new 52-week high of $25.40 after announcing a $10 million milestone payment from Sanofi and the initiation of a Phase 3 trial for bexobrutideg. Despite positive analyst sentiment, with a consensus "Moderate Buy" rating and a $34 price target, the company remains unprofitable and missed recent EPS and revenue estimates. Insider selling, though under pre-arranged plans, also occurred, raising some bearish concerns.
Nurix Therapeutics stock hits 52-week high at $25.22 By Investing.com
Nurix Therapeutics (NRIX) stock has reached a 52-week high, closing at $25.22, signifying a 140.54% increase over the past year. This performance, including a 118% total return, is supported by strong investor confidence and recent positive analyst updates following the company's Q2 2026 earnings report and a significant collaboration deal with Roche. Despite appearing slightly overvalued according to InvestingPro, analysts from Mizuho, Truist Securities, Baird, and Morgan Stanley have all raised their price targets, maintaining positive ratings.
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,111 Shares
Gwenn Hansen, an insider at Nurix Therapeutics (NASDAQ:NRIX), sold 4,111 shares of the company's stock for approximately $100,144 under a Rule 10b5-1 plan, reducing her ownership by 3.39%. This transaction follows previous sales in July and June. Despite the insider selling, analysts maintain a "Moderate Buy" rating for NRIX with a consensus price target of $34, even though the company recently missed quarterly earnings and revenue expectations.
Houte Hans Van Sells 4,761 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock
Nurix Therapeutics CFO Houte Hans Van sold 4,761 shares of the company's stock for approximately $116,000, reducing his ownership by 10.6% to 40,166 shares. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. The company's shares opened at $24.69, near their 52-week high, despite Nurix reporting a quarterly loss and revenue below analyst expectations.
Form 4 Nurix Therapeutics Inc For: 4 August By Investing.com
This article from Investing.com is a simple, brief notice about a Form 4 filing for Nurix Therapeutics Inc. The filing was made for August 4th, 2026. The article itself contains no further details about the content of the Form 4.
Nurix Therapeutics (NRIX) insider plans $385K sale of stock options and RSUs
Nurix Therapeutics (NRIX) insider Christine Ring has filed to sell up to 16,589 common shares, valued at approximately $385,030.69, through Morgan Stanley Smith Barney LLC. The shares originate from stock option exercises and restricted stock units. This filing also references previous Rule 10b5-1 sales, including a significant transaction of 28,935 shares for over $580,000 on June 25, 2026.
NRIX Looks 273.5% Overvalued on GF Value™
Nurix Therapeutics Inc (NRIX) has received a $10 million milestone payment from Sanofi for a Phase 1 clinical trial, highlighting pipeline progress. Despite this, the company appears significantly overvalued, with a Price-to-Sales ratio of 63.44 and a GF Value indicating it is 273.5% overvalued. The GF Score of 61 reflects strong growth and momentum but poor profitability and valuation, with mixed signals from guru accumulation and insider selling.
Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader
Nurix Therapeutics received a $10 million milestone payment from Sanofi as Sanofi initiated a Phase 1 clinical trial for a STAT6 degrader. This payment reflects progress in their collaboration. Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and autoimmune diseases.
Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Needham & Company LLC
Needham & Company LLC has reiterated its "buy" rating for Nurix Therapeutics (NASDAQ:NRIX), setting a price target of $34.00, suggesting a potential upside of over 40%. This comes despite Nurix reporting weaker-than-expected quarterly results with an EPS loss of $0.81 and revenue of $9.04 million, both missing analyst consensus estimates. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapies for oncology and immunology, and currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $34.00.
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Nurix Therapeutics, Inc. announced it has received a $10 million milestone payment from Sanofi following the initiation of a Phase 1 clinical trial for SAR448272/NX-3911, an oral STAT6 degrader for type 2 inflammatory diseases. This payment brings the total received by Nurix under its collaboration with Sanofi to approximately $139 million, with potential for an additional $453 million in future milestones and royalties. Nurix also retains a co-development and co-promotion option in the U.S. for the STAT6 program.
Nurix Therapeutics chief legal officer Christine Ring sells $382k stock
Christine Ring, Nurix Therapeutics' Chief Legal Officer, sold 16,589 shares worth $382,358 on August 3, 2026, while also acquiring 5,787 shares through stock options for $50,462. These transactions, executed under a Rule 10b5-1 plan, leave her with 9,110 direct shares and 122,824 employee stock options. Analysts have shown increased confidence in Nurix, raising price targets due to a strategic collaboration with Roche.
Nurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care
Nurix Therapeutics has enrolled the first patient in its global Phase 3 DAYBreak CLL-306 trial for bexobrutideg, a potential best-in-class BTK degrader, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This registrational study, conducted in collaboration with Roche, compares bexobrutideg against pirtobrutinib, the current standard of care, to evaluate its potential superiority. The trial aims to enroll approximately 620 patients, with dual primary endpoints of objective response rate and progression-free survival.
Perceptive Advisors LLC Has $57.52 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX
Perceptive Advisors LLC increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 4.4% in the first quarter, now owning 3.71 million shares valued at $57.52 million, representing 3.59% of the company. Despite Nurix missing Q1 analyst estimates for earnings and revenue, Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $34.00. However, company insiders have recently sold shares, primarily to cover tax obligations from vested equity awards.
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 3,847 Shares of Stock
Nurix Therapeutics insider Gwenn Hansen recently sold 3,847 shares of NRIX stock for $23.38 per share, totaling $89,942.86. This sale was primarily to cover tax withholding obligations from vested equity awards. Despite missing recent earnings and revenue estimates, analysts generally maintain a "Moderate Buy" rating with a consensus price target of $34.00 for the company.
Houte Hans Van Sells 2,845 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock
Nurix Therapeutics CFO Houte Hans Van sold 2,845 shares of the company's stock for $66,516.10 to cover tax withholding on vested equity awards, reducing his direct holdings by 5.96%. NRIX shares traded near their 52-week high, despite the company reporting quarterly earnings and revenue below analyst expectations. Analysts maintain a "Moderate Buy" rating with an average price target of $34.00, reflecting optimism despite recent financial performance.
The Technical Signals Behind (NRIX) That Institutions Follow
An analysis of Nurix Therapeutics Inc. (NASDAQ: NRIX) reveals neutral near and mid-term readings but a positive long-term bias. The article highlights a mid-channel oscillation pattern and a significant 64.5:1 risk-reward setup, targeting an 18.3% gain against 0.3% risk. It also outlines specific AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies.
Vanguard Capital Management (NRIX) discloses 5.03% Nurix Therapeutics ownership stake
Vanguard Capital Management LLC and its affiliates have disclosed a beneficial ownership stake of 5.03% in Nurix Therapeutics Inc. (NRIX), as per a Schedule 13G SEC filing. This amounts to 5,202,025 shares of common stock as of June 30, 2026. Vanguard holds sole voting power over 706,496 shares and sole dispositive power over all 5,202,025 shares, with no individual person's interest exceeding 5% through these holdings.
Form 4 Nurix Therapeutics Inc For: 30 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Nurix Therapeutics Inc., pertaining to transactions made on July 30. The brief update includes the stock symbol NRIX and indicates a slight price change of -1.57%.
Nurix therapeutics CFO Hans van Houte sells $66,524 in shares
Hans van Houte, CFO of Nurix Therapeutics (NASDAQ:NRIX), sold 2,845 shares totaling approximately $66,524 to cover tax obligations from vested restricted stock units. This sale occurred while the stock trades near its 52-week high after a 98% gain. Concurrently, van Houte acquired 10,180 shares through RSU vesting and now directly holds 44,927 shares.
Nurix therapeutics CFO Hans van Houte sells $66,524 in shares
Nurix Therapeutics CFO Hans van Houte sold 2,845 shares to cover tax withholding obligations from restricted stock unit vesting, totaling approximately $66,524. This transaction occurred as the stock trades near its 52-week high and has seen a 98% gain over the past year. Concurrently, Mr. van Houte acquired 10,180 shares through RSU vesting, increasing his direct holdings to 44,927 shares.
Nurix therapeutics CSO Gwenn Hansen sells $89,953 in stock
Gwenn Hansen, CSO of Nurix Therapeutics, sold 3,847 shares worth $89,953 to cover tax obligations related to vesting restricted stock units. On the same day, she acquired 10,180 shares through RSU vesting. This transaction occurs as NRIX stock trades near a 52-week high, and analysts maintain positive ratings following the company's Q2 2026 earnings and a collaboration with Roche.
Nurix Therapeutics chief legal officer sells $89,953 in stock
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 3,847 shares worth $89,953 on July 30, 2026, to cover tax obligations from RSU vesting. Concurrently, she acquired 10,180 shares through RSU conversions. This transaction occurred amidst a 109% surge in NRIX stock over the past year, and various analysts have upgraded price targets following the company's collaboration with Roche.
Nurix therapeutics CSO Gwenn Hansen sells $89,953 in stock
Gwenn Hansen, CSO of Nurix Therapeutics, sold 3,847 shares of common stock for $89,953 to cover tax obligations from restricted stock unit vesting. This transaction occurred as NRIX stock reached near its 52-week high, with the company also recently acquiring 10,180 shares through RSU vesting as part of her compensation. Analysts maintain positive ratings on Nurix Therapeutics following its Q2 2026 earnings and a significant collaboration with Roche.
Stempoint Capital LP Makes New $4.89 Million Investment in Nurix Therapeutics, Inc. $NRIX
Stempoint Capital LP has made a new $4.89 million investment in Nurix Therapeutics, acquiring 315,226 shares, representing a 0.30% stake. This comes amidst mixed news for Nurix, with other institutional investors increasing positions and analysts maintaining a "Moderate Buy" consensus despite the company missing recent earnings expectations. Insider selling also occurred, while several firms raised their price targets for NRIX, offsetting a downgrade from Wells Fargo.
Nurix Therapeutics chief legal officer sells $89,953 in stock
Christine Ring, Chief Legal Officer at Nurix Therapeutics, sold $89,953 worth of stock on July 30, 2026, to cover tax withholding obligations from RSU vesting, not through discretionary trades. These sales occurred as the NRIX stock trades near its 52-week high after a significant 109% surge over the past year, though InvestingPro analysis suggests it may be overvalued. Concurrently, Ms. Ring also acquired 10,180 shares through RSU vesting at $0 per share, increasing her direct holdings to 19,912 shares.
Nurix Therapeutics, Inc. $NRIX is Redmile Group LLC's 5th Largest Position
Redmile Group LLC slightly reduced its stake in Nurix Therapeutics (NASDAQ:NRIX) by 4.5% during Q1, though it remains their 5th largest holding, valued at $119.86 million. Other major investors like Vanguard Group, General Atlantic, and Morgan Stanley significantly increased their positions in the company. Wall Street analysts have a "Moderate Buy" rating for Nurix Therapeutics, with an average price target of $34.00.
Nurix Therapeutics Inc (NRIX) Financial Health: Profitability & Balance Sheet Analysis
Nurix Therapeutics Inc (NRIX) currently has a financial score of 6.71, ranking 225 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status and average operating efficiency. The company's latest quarterly revenue was $9.04 million, a significant year-over-year decrease of 79.47%, with net profit declining by 106.00% year-over-year. Key financial health indicators like cash and cash equivalents, total assets, total liabilities, and free cash flow data have not been disclosed by the company.
Morgan Stanley Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $38
Morgan Stanley has reiterated its Buy rating on Nurix Therapeutics (NRIX.US) and maintained a target price of $38. This indicates a continued positive outlook from the investment bank on the company's stock performance.
